摘要
罗库溴铵是目前临床使用中起效最快的中时效非去极化肌松药，挥发性吸入麻醉药可明显增强罗库溴铵的肌松效应，延长其作用时间，减少使用剂量；也可降低抗胆碱酯酶药拮抗罗库溴铵的肌松效果，因此有必要适时停用或降低吸入麻醉药的浓度，以避免术后肌张力恢复时间延长，减少术后残余肌松作用引起的呼吸系统并发症。此文就挥发性吸入麻醉药对罗库溴铵肌松作用的影响作一综述。
Rocuronium bromide is a non-depolarizing neuromuscular blocking agent with the shortest onset time and intermediate duration of action in the clinical use at present. In clinical scenario, inhalational anesthetic agents can significantly enhance the neuromuscular blockade effect, prolong the duration of action and reduce the dosage of rocuronium. At the same time, inhalational anesthetic agents can retard the reversal of rocuronium by anticholinesterase agents. Above reason had been taken as excuses of earlier stopping or decreasing concentrations of inhalational anesthetic agents to avoid retarding recovery time of muscular tension and reduce respiratory complications related to postoperative residual muscular relaxant.
出处
《国际麻醉学与复苏杂志》
CAS
2008年第5期470-473,共4页
International Journal of Anesthesiology and Resuscitation
关键词
罗库溴铵
吸入麻醉药
神经肌肉阻滞
残余肌松
呼吸系统并发症
rocuronium
inhalational anesthetic agents
neuromuscular blockade
residual relaxant
rspiratory complications
